United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$353.00 USD
+1.67 (0.48%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $353.03 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
Brokerage Reports
0 items in cart
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 161 - 180 ( 611 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4 Sales Beat & Cash Rich; Next: Tyvaso?/PH-ILD PDUFA in April
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Year of Anticipated Launches Builds Pipeline From PAH and PH-ILD
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Positive TYVASO DPI- Data; NDA Filing Anticipated in April With Priority Review
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Key Takeaways from Tyvaso/PH-ILD Science Session
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso/PH-ILD Setting Positive Tone in 2021 Ahead of Value- Driving Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
PRV Bought for $105M Creates Expedited Regulatory Review for Tyvaso DPI
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Treprostinil/IPF: FDA Grants ODD; On-Track to Start Ph3 TETON Study in 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Evolving PAH and Lung Disease Platform Presents Several Paths Yet to Be Distinguished
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Strong Q3, Plenty of Cash and Positive 2021 Outlook
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso? Safety Data at CHEST 2020 Adds Momentum to Catalyst-Rich 2021 (Erratum)
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L